Preparing for a New Era in Alzheimer's Disease: Debating New Targeted Biomarkers and Therapeutic Approaches : Episode 1
Apolipoprotein E4 in Alzheimer’s Disease
Sharon Cohen, MD, and Marwan Sabbagh, MD, differentiate between the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD), and highlight known risk factors, including the contribution of ApoE gene polymorphism and copy numbers.
Now Viewing
EP: 1.Apolipoprotein E4 in Alzheimer’s Disease
EP: 2.Importance of Early Diagnosis of Alzheimer’s Disease
EP: 3.Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease
EP: 4.Amyloid Cascade Hypothesis of Alzheimer’s Disease
EP: 5.Contribution of Multiple Pathways to the Development of Alzheimer’s Disease
EP: 6.Utilization of Neuroimaging in Alzheimer’s Disease
EP: 7.CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease
EP: 8.Utilization of APOE4 Genotype in Management of Alzheimer’s Disease
EP: 9.Alzheimer’s Disease Pipeline
EP: 10.The Future Outlook for Alzheimer’s Disease
Video content above is prompted by the following question(s):
- How are different stages of Alzheimer’s disease (AD; preclinical AD, prodromal AD, and AD with dementia) defined?
- What are known risk factors for Alzheimer's disease?
- Contribution of ApoE gene polymorphism and copy numbers
- When do patients with Alzheimer’s typically present to the clinic?
- What are known risk factors for Alzheimer's disease?
Recent Videos
Related Content
